Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) Operating Expenses (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Operating Expenses for 14 consecutive years, with $64002.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 73.74% year-over-year to $64002.0, compared with a TTM value of $298856.0 through Nov 2025, down 40.24%, and an annual FY2025 reading of $271691.0, down 61.91% over the prior year.
  • Operating Expenses was $64002.0 for Q4 2025 at CNBX Pharmaceuticals, down from $129731.0 in the prior quarter.
  • Across five years, Operating Expenses topped out at $1.1 million in Q4 2021 and bottomed at $36837.0 in Q4 2024.
  • Average Operating Expenses over 5 years is $366308.7, with a median of $261417.5 recorded in 2023.
  • The sharpest move saw Operating Expenses crashed 85.9% in 2024, then surged 146.95% in 2025.
  • Year by year, Operating Expenses stood at $1.1 million in 2021, then plummeted by 68.77% to $346790.0 in 2022, then fell by 24.64% to $261337.0 in 2023, then plummeted by 85.9% to $36837.0 in 2024, then skyrocketed by 73.74% to $64002.0 in 2025.
  • Business Quant data shows Operating Expenses for CNBX at $64002.0 in Q4 2025, $129731.0 in Q3 2025, and $40380.0 in Q2 2025.